Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2019 23:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences, Inc. Prices Public Offering of 12,500,000 shares of Common Stock

SOUTH SAN FRANCISCO, Calif., June 18, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
June 17, 2019 16:01 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 17, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
June 17, 2019 06:00 ET | Source: Calithera Biosciences, Inc.

Calithera Achieves Positive Topline Results in Randomized Phase 2 ENTRATA Study of Telaglenastat with Everolimus in Renal Cell Carcinoma

-Doubled median progression-free survival (PFS) in heavily pre-treated patients with advanced renal cell carcinoma -Provides first clinical proof of concept for glutaminase inhibitor telaglenastat ...
May 09, 2019 16:06 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights

--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on May 9, 2019-- SOUTH SAN FRANCISCO, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc....
May 03, 2019 07:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019

SOUTH SAN FRANCISCO, Calif., May 03, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biopharmaceutical company pioneering the discovery and development of...
April 02, 2019 07:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Presents New Preclinical Data for CB-708 at AACR Annual Meeting 2019

SOUTH SAN FRANCISCO, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
March 26, 2019 07:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib

SOUTH SAN FRANCISCO, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small...
March 07, 2019 16:06 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports Fourth Quarter 2018 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
March 05, 2019 07:05 ET | Source: Calithera Biosciences, Inc.

Calithera to Present at Cowen & Company 39th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
March 04, 2019 07:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019

SOUTH SAN FRANCISCO, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...